By

Lundbeckfonden
Lund, Sweden, 08.00 CET, 20 February 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces the publication of its Q4 and Year-End Report – January – December 2017. 2017 net sales increased by...
Cambridge, Mass. (Business Wire) February 13, 2018 – Imara, Inc. today announced it has dosed the first patient in its Phase 2a clinical trial, evaluating the safety, pharmacokinetics and pharmacodynamics of escalating doses of IMR-687 in adult patients with sickle cell disease (SCD). IMR-687 is a highly potent and selective inhibitor of phosphodiesterase-9 (PDE9i) in blood...
Et hold hovedpineforskere fra Rigshospitalet forbereder et forsøg, hvor de vil give deltagerne anfald af verdens værste hovedpine: Hortons hovedpine – også kendt som selvmordshovedpine. Vil man gøre noget godt for menneskeheden, skal man udvikle en effektiv behandling mod Hortons hovedpine. For blandt de cirka 100 forskellige former for hovedpine, videnskaben kender, er Hortons den...
Lund, Sweden, 08.00 CET, 6 February 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform, will publish its Year-end Report for January-December 2017 on Tuesday 20 February 2018 at 08.00am CET. The Company will...
Lund, Sweden, 18:00 CET 1 February 2018 – BONESUPPORT HOLDING AB’s subsidiary BONESUPPORT AB has repaid the remaining debt under the loan facility from Kreos Capital V (UK) Ltd. The original loan agreement, which was signed in September 2016 included two tranches, one of EUR 13.4 million and one of EUR 8.9 million. BONESUPPORT has...
Signalstoffet dopamin motiverer os til at handle – både fornuftigt og nogle gange decideret ufornuftigt. Som optakt til offentliggørelsen af vinderne af The Brain Prize 2018 d. 6. marts, kan du her læse et interview med en af sidste års vindere, professor Wolfram Schultz, om hans banebrydende forskning i hjernens belønningssystem, dopamin og afhængighed. Hjernens...
Lund, Sweden, 18:00 CET 31 January 2018 – During January, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 31 January 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 50,368,766. About BONESUPPORT™ BONESUPPORT is an innovative and...
Lund, Sweden 08.30 CET, 23 January 2018 – BONESUPPORT (Nasdaq Stockholm: BONEX), an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform, announces that the Board of Directors has appointed Emil Billbäck as the new CEO of...
Lund, Sweden, 08.00 CET, 22 January 2018 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique platform  announces that a paper “Gelatin- hydroxyapatite-calcium sulphate based biomaterial for long term sustained delivery of bone morphogenic protein-2 and zoledronic...
SAN DIEGO – January 8, 2018 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, with a near-term focus on deadly fungal pathogens, today announced that Alan Fuhrman has been appointed as Chief Financial Officer of Amplyx. The Company also announced today that Ciara Kennedy, Ph.D., Chief Executive Officer of Amplyx, will present...
1 2 3 9